BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXL) has engaged two consulting firms to evaluate the commercial and market access potential of its cancer therapy candidate Bria-IMT, according to a press release from the clinical-stage biotechnology company.

Charles River Associates (Nasdaq: CRAI) has been retained to assess epidemiology, pricing, prescriber dynamics, and market access potential for Bria-IMT in metastatic breast cancer in the United States. Separately, Kaleio, Inc. has been engaged to support brand strategy and commercial-readiness planning.

Bria-IMT is currently being evaluated in a pivotal Phase 3 clinical trial (NCT06072612) in metastatic breast cancer and has not received regulatory approval. BriaCell described the engagements as a commercial-readiness step in preparation for potential future commercialization, contingent on successful clinical development and regulatory approvals.